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Introduction: The aim of this study was to investigate the kinetics of immunoglobulin M (IgM) during the different
stages of sepsis.
Methods: In this prospective multicenter study, blood sampling for IgM measurement was done within the first
24 hours from diagnosis in 332 critically ill patients; in 83 patients this was repeated upon progression to more severe
stages. Among these 83 patients, 30 patients with severe sepsis progressed into shock and IgM was monitored daily
for seven consecutive days. Peripheral blood mononuclear cells (PBMCs) were isolated from 55 patients and stimulated
for IgM production.
Results: Serum IgM was decreased in septic shock compared to patients with systemic inflammatory response
syndrome (SIRS) and patients with severe sepsis. Paired comparisons at distinct time points of the sepsis course
showed that IgM was decreased only when patients deteriorated from severe sepsis to septic shock. Serial
measurements in these patients, beginning from the early start of vasopressors, showed that the distribution of IgM
over time was significantly greater for survivors than for non-survivors. Production of IgM by PBMCs was significantly
lower at all stages of sepsis compared with healthy controls.
Conclusions: Specific changes of circulating IgM occur when patients with severe sepsis progress into septic shock.
The distribution of IgM is lower among non-survivors.Introduction
Although initially considered a state of hyperactivity of the
innate and adaptive immune systems, it is currently under-
stood that severe sepsis and septic shock are characterized
by a functional state of immunoparalysis [1]. This involves
not only monocytes and macrophages, but also CD4 lym-
phocytes and B lymphocytes [2]. Under normal conditions,
CD4 lymphocytes orchestrate B lymphocyte responses for
the secretion of the polyvalent immunoglobulin M (IgM)
antibodies that are of crucial importance for the opso-
nization and the subsequent rapid clearance of the in-
vading microorganisms [3]. Immunoparalysis of sepsis is* Correspondence: egiamarel@med.uoa.gr
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distribution, and reproduction in any mediumcharacterized by defective B-lymphocyte responses to-
ward low immunoglobulin production [2].
To this end, it was expected that the intravenous ad-
ministration of immunoglobulin preparations enriched
in IgM would be beneficial for patients with severe sepsis
and septic shock. On the contrary, most of the conducted
randomized clinical trials (RCT) yielded contradictory re-
sults [4,5], despite one meta-analysis indicating that IgM
preparations significantly decrease the relative risk of death
in both adult and child populations [4].
The existing controversies of conducted RCTs may de-
rive from our incomplete understanding of the kinetics of
IgM over the time course of sepsis. The current study was
designed in order to embed into the changes of circulating
IgM levels of patients upon progression to the more severe
stages of sepsis in relation with the production of IgM from
circulating lymphocytes and with the final outcome.BioMed Central Ltd. This is an open access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Study design
This prospective multicenter study was conducted from
January 2010 to December 2010 in 27 departments across
Greece participating in the Hellenic Sepsis Study Group.
The participating departments were 15 intensive care units
(ICUs), seven departments of Internal Medicine, two de-
partments of pulmonary medicine, two departments of
surgery and one department of urology.
Patients with signs of systemic inflammatory response
syndrome (SIRS) either admitted to the emergency depart-
ment or hospitalized in the general ward or in the ICU
were eligible. Written informed consent was provided by
the patients or by their first-degree relatives for patients
unable to consent. The study protocol was approved
by the Ethics Committees of the participating hospitals
(Ethics Committee of Alexandra Athens General Hospital;
Ethics Committee of ‘Aghia Olga’Athens General Hospital;
Ethics Committee of Argos General Hospital; Ethics Com-
mittee of ATTIKON University Hospital; Ethics Commit-
tee of ‘G. Gennimatas’ Athens General Hospital; Ethics
Committee of ‘G. Gennimatas’ Thessaloniki General Hos-
pital; Ethics Committee of Evangelismos Athens General
Hospital; Ethics Committee of Chios General Hospital;
Ethics Committee of Ippocrateion General Hospital; Ethics
Committee of Laikon Athens General Hospital; Ethics
Committee of ‘Korgialeneion-Benakeion’ Athens General
Hospital; Ethics Committee of Lamia General Hospital;
Ethics Committee of Larissa University Hospital; Ethics
Committee of Nafplion General Hospital; Ethics Commit-
tee of Ptolemaida General Hospital; Ethics Committee of
Sismanogleion Athens General Hospital; Ethics Committee
of Sotiria Athens General Hospital; Ethics Committee of
Sparti General Hospital; Ethics Committee of Thriassion
Elefsis General Hospital; and Ethics Committee of Tzaneion
Piraeus General Hospital). Each patient was enrolled once.
Inclusion criteria were: (a) age ≥18 years; (b) diagnosis of
SIRS, sepsis, severe sepsis or septic shock; and (c) SIRS due
to acute pancreatitis or sepsis due to specific infections.
These infections were: community-acquired pneumonia
(CAP), ventilator-associated pneumonia (VAP), acute
pyelonephritis (UTI), acute intra-abdominal infection (IAI)
and primary bacteremia (BSI); and (d) first blood sampling
within 24 hours from diagnosis.
Exclusion criteria were (a) infection by the human im-
munodeficiency virus type 1; (b) neutropenia defined as
less than 1,000 neutrophils/mm3; (c) chronic intake of
corticosteroids defined as systemic intake of more than
1 mg/kg of equivalent prednisone for more than one
month; and (d) other types of immunodeficiency like organ
transplantation, hematologic malignancies and intake of
chemotherapy.
SIRS was diagnosed by the presence of at least two of
the following [6]: (a) core temperature >38°C or <36°C,(b) Pco2<32 mmHg or more than 20 breaths/min, (c) pulse
rate >90/min, and (d) white blood cells >12,000/mm3
or <4,000/mm3 or >10% of band forms. Sepsis was de-
fined as any microbiologically or clinically documented
infection complicated by SIRS. Patients with sepsis were
classified as suffering from uncomplicated sepsis, severe
sepsis or septic shock, according to standard definitions
[6]. Multiple organ dysfunctions syndrome (MODS) was
defined by the same criteria [6]. Acute pancreatitis, CAP,
VAP, UTI, IAI and BSI were defined according to stand-
ard definitions [7-11].
For each patient a complete diagnostic workup was
performed comprising history, thorough physical exam-
ination, white blood cell (WBC) count, blood biochemis-
try, arterial blood gas, blood cultures from peripheral
veins and central lines, urine cultures, chest X-ray and
chest and abdominal computed tomography if appro-
priate. If necessary, quantitative cultures of tracheo-
bronchial secretions (TBS) or bronchoalveolar lavage
(BAL) were performed and evaluated as previously de-
scribed [9]. Survival was recorded for 28 days and at hos-
pital discharge. Clinical and demographic data were
recorded on a case report form (CRF). All CRFs were
monitored by an independent monitor blinded to the
study design.
Blood sampling and laboratory procedure
For all enrolled patients and for 35 healthy volunteers 5 ml
of blood was sampled within the first 24 hours from
diagnosis. From this volume: (a) 2 ml was collected into
sterile, pyrogen- and anticoagulant-free tubes (Vacutainer,
Becton Dickinson, Cockeysville, MD, USA) for quantitative
measurement of IgM; and (b) 3 ml was collected into
EDTA-coated tubes (Vacutainer) for the measurement
of the absolute counts of B lymphocytes. From 55 pa-
tients and 20 healthy volunteers another 8 ml was col-
lected into heparin-coated tubes (Vacutainer) and used
for the isolation of peripheral blood mononuclear cells
(PBMCs). For 83 patients, blood sampling was repeated
on the day of worsening of sepsis stage. For 30 pa-
tients who progressed into septic shock, blood was
sampled daily for seven days starting immediately after
the start of vasopressors. Tubes were transported by a
courier service within the same day to the Laboratory of
Immunology of Infectious Diseases of the 4th Department
of Internal Medicine at ATTIKON University Hospital
of Athens. Tubes were centrifuged and serum was kept
frozen at -70°C until assayed. IgM was estimated in
duplicate by an enzyme-linked immunosorbent assay
(e-Bioscience Inc., San Diego, CA, USA) following the
manufacturer’s instructions; the lower detection limit
was 20 ng/ml. All estimations were performed and re-
ported by two technicians who were blinded to clinical
information.
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the UK NEQAS quality control system for leukocyte
immunophenotyping (registration number 40926). In this
laboratory, the absolute count of B lymphocytes was mea-
sured as described elsewhere [12]. Briefly, red blood cells
were lysed with ammonium chloride 1.0 mM. White blood
cells were washed three times with phosphate-buffered sa-
line (PBS) (pH 7.2) (Merck, Darmstadt, Germany) and sub-
sequently incubated for 15 minutes in the dark with the
monoclonal antibody anti-CD19 at the flurochrome fluor-
escein isothiocyanate (FITC, emission 525 nm, Immuno-
tech, Marseille, France) using fluorospheres (Immunotech)
for the determination of absolute counts. One IgG isotypic
negative control at the fluorocolor FITC was analyzed for
every patient. Cells were analyzed after running through
the EPICS XL/MSL flow cytometer (Beckman Coulter,
Inc., Miami, FL, USA) with gating for mononuclear cells
based on their characteristic forward scatter/side scatter
(FS/SS) scattering.
The isolation of PBMCs was limited to 55 patients be-
cause these samples should come from patients hospital-
ized at study sites close to the central laboratory. This
allowed the time from blood collection until processing
to be less than 30 minutes. As such, PBMCs were studied
from patients hospitalized at the ATTIKON University
Hospital that is close to the central laboratory of the study.
Production of IgM was studied according to a procedure
described elsewhere [13]. Heparinized venous blood was
layered over Ficoll Hypaque (Biochrom, Berlin, Germany)
and centrifuged for 20 minutes at 1400 g. Separated
PBMCs were washed three times with ice-cold PBS
(pH: 7.2) (Biochrom) and counted in a Neubauer cham-
ber. Their viability was more than 99% as assessed by try-
pan blue exclusion of dead cells. They were then diluted
in RPMI 1640 enriched with 2 mM of L-glutamine, 10%
fetal bovine serum (Biochrom), 100 U/ml of penicillin G,
100 μg/ml of gentamicin and 10 mM of pyruvate and sus-
pended into wells of a 96-well plate (Greiner, Alphen a/d
Rijn, The Netherlands). The final volume per well was
200 μl with a density of 2 ×106 cells/ml. PBMCs were incu-
bated in the absence or presence of 5 μg/ml of the lympho-
cyte agonist phytohemagglutin (PHA) of Phaseolus vulgaris
(PHA-L, Roche Diagnostics GMBH, Mannheim, Germany)
for 24 or 72 hours at 37°C in 5% CO2 atmosphere.
At the end of the incubation, the plates were centrifuged.
Supernatants were kept stored at -70°C until assayed.
Concentrations of IgM were measured at the end of the
72-hour incubation period; those of tumor necrosis factor
alpha (TNFα) were measured at the end of the 24-hour
incubation period. Measurements were done in duplicate
and IgM was measured as described above. TNFα was
measured by an enzyme-linked immunosorbent assay
(R&D Minneapolis, MI, USA). The lower detection limit
was 40 pg/ml.Study endpoints
The primary endpoint was the over-time changes of
IgM serum levels of patients upon progression to septic
shock in relation with the final outcome that is survival
or 28-day mortality. The secondary study endpoint was
the impact of sepsis on production of IgM from circulat-
ing lymphocytes.
Statistical analysis
Demographic characteristics of enrolled patients were
provided as percentages for qualitative variables and as
means ± standard error of the mean (SE) or medians and
interquartile ranges for quantitative variables. Comparisons
between groups were done by the X2 test for qualitative
variables and by ANOVA with post hoc Bonferroni correc-
tions for quantitative variables.
Serum concentrations of IgM were expressed as me-
dians and 95% confidence intervals (CI). Comparisons
between groups were done by the Mann-Whitney U test
with corrections by Bonferroni for multiple testing. Paired
comparisons of serum IgM at baseline and upon progres-
sion of the same patients to a more severe stage were done
by the Wilcoxon’s rank sum test. For every patient with
septic shock, the area under the curve (AUC) of IgM over
time for seven days was measured by the linear trapezoidal
rule. Comparison between survivors and non-survivors
was done by Student’s t test.
Concentrations of IgM and of TNFα in supernatants
of PBMCs were expressed as means ± SE. Comparisons
between groups were done by the Kruskal-Wallis test with
corrections by Bonferroni for multiple testing. Patients
were also divided into ‘non-IgM’ and ‘IgM-producers’ if the
concentrations of IgM in supernatants of PBMCs were
below the limit of detection or not. Comparisons were
done by the X2 test.
Values of P below 0.05 were considered significant.
Results
A total of 351 patients were screened and 332 were en-
rolled (Figure 1). The demographic characteristics of en-
rolled patients in relation with the severity of critical
illness are shown in Table 1. As expected, acute physiology
and chronic health evaluation II (APACHE II) score, WBC
counts, C-reactive protein and mortality were greater in
the more severe stages of sepsis.
The study end point was the kinetics of serum IgM
upon progression from severe sepsis to septic shock in
relation with final outcome. To reach this end point, a
three-step approach was followed (Figure 1) (a) circulating
IgM was compared between critically ill patients with vary-
ing severity; (b) circulating IgM was measured at baseline
and on the first day of worsening; and (c) distribution of
IgM was compared over time between survivors and non-
survivors from septic shock.
Figure 1 Study flow chart. Ig, immunoglobulin; MODS, multiple organ dysfunction syndrome; SIRS, systemic inflammatory response syndrome.
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34.9 mg/dl in SIRS; 23.0 mg/dl in sepsis; 36.2 mg/dl in
severe sepsis; and 21.9 mg/dl in septic shock. Statistical
analysis showed that serum IgM was decreased in septic
shock compared to healthy volunteers (P = 0.001), to pa-
tients with SIRS (P = 0.028) and to patients with severe
sepsis (P <0.0001) but not to patients with uncomplicated
sepsis (P = 0.754) (Figure 2).
Paired comparisons of IgM were done for 83 patients at
two specific time points: on initial diagnosis and on wors-
ening. These measurements involved: 13 patients initially
diagnosed with uncomplicated sepsis who worsened into
severe sepsis; 16 patients initially diagnosed with uncom-
plicated sepsis who worsened into septic shock; 49 patients
initially diagnosed with severe sepsis who worsened into
septic shock; and five patients initially diagnosed with sep-
tic shock who worsened into MODS (Figure 3). From all
these paired comparisons, significant changes of circulating
IgM were found only between severe sepsis and septic
shock; IgM was significantly decreased upon worsening
from severe sepsis into septic shock (P = 0.039).
Within the enrolled population with septic shock,
serum IgM did not differ between survivors and non-
survivors (median IgM of survivors 23.1 mg/dl and of
non-survivors 20.7 mg/dl, P = 0.442). The time curves of
IgM were designed for 30 patients with severe sepsis
who progressed into septic shock. Sampling was started
on the day of the start of vasopressors and lasted for
seven consecutive days. Separate curves were designedfor survivors and non-survivors. These curves suggested
that circulating IgM remained stable and at low levels in
non-survivors whereas IgM of survivors increased to an
early peak and then gradually decreased. As a conse-
quence, the distribution of IgM expressed by the AUC of
serum IgM over time was significantly greater for survi-
vors than for non-survivors. This finding was similar
both when outcome was assessed after 28 days and at
hospital discharge (Figure 4A and 4B).
Production of IgM by PBMCs of 55 patients was also
studied. From these patients, 24 had uncomplicated sepsis,
20 severe sepsis and 21 septic shock. Respective mean ±
SD age was 66.5 ± 18.7, 76.4 ± 9.2 and 60.0 ± 21.4 years;
mean ± SD APACHE II score was 10.7 ± 5.4, 17.4 ± 4.3
and 23.6 ± 4.8; and mean ± SD white blood cell count was
12,226.4 ± 5,262.0, 16,384.0 ± 11,294.0 and 17,130.9 ±
9,793.7/mm3.
High production of both IgM and TNFα was found by
the PBMCs of healthy volunteers after stimulation with
the selective lymphocyte agonist PHA. Production of
IgM and of TNFα was significantly lower at all stages
of sepsis compared with healthy controls (Figure 5A
and 5B). Furthermore, the rate of ‘IgM producers’ was sig-
nificantly lower among patients with septic shock than
among patients at all other sepsis stages (Figure 5C).
Discussion
The present study is the largest cohort to the best of our
knowledge that describes the kinetics of circulating IgM
Table 1 Demographic characteristics of patients enrolled in the study
SIRS (n= 41) Sepsis (n= 100) Severe sepsis (n= 113) Septic shock (n= 78) P
Male/female 25/16 50/50 57/56 37/41 0.598*
Age (years, mean ± SD) 66.1 ± 10.9 66.6 ± 19.8 73.0 ± 14.1 70.0 ± 16.5
APACHE II (mean ± SD) 5.9 ± 3.3 13.3 ± 5.9a 19.7 ± 6.8b, c 23.2 ± 6.8d, e, f
WBCs (/mm3, mean ± SD) 11270.4 ± 4364.8 14406.8 ± 6405.6 14982.3 ± 9682.4 16442.9 ± 9446.3d
Lymphocytes (/mm3, mean ± SD) 2298.3 ± 422.1 1942.0 ± 224.7 478.0 ± 236.2 997.3 ± 750.8
CD19-cells (/mm3, mean ± SD) 182.9 ± 40.7 86.7 ± 21.5 40.9 ± 10.0 43.5 ± 19.1
C-reactive protein (mg/l), median (IQR) 4.3 (4.9) 100.8 (140.8)a 141.7 (153.3)b 153.0 (137.5)d
Infection (n %) <0.0001*
UTI 44 (44.0) 24 (21.2) 13 (16.7)
CAP 15 (15.0) 32 (28.3) 30 (38.5)
IAI 24 (24.0) 17 (15.0) 8 (10.3)
BSI 14 (14.0) 15 (13.3) 17 (21.8)
VAP 3 (3.0) 25 (22.1) 10 (12.8)
Acute pancreatitis 41 (100)
Type of IAI (n, %) 0.238*
Peritonitis after gut rupture 1 (1.0) 2 (1.8) 2 (2.6)
Acute cholecystitis 4 (4.0) 2 (1.8) 0 (0)
Acute cholangitis 14 (14.0) 7 (6.2) 3 (3.8)
Acute diverticulitis 2 (2.0) 0 (0) 0 (0)
Intrabdominal abscess 3 (2.0) 5 (4.4) 3 (3.8)
Isolated microorganisms (n, %) <0.0001*
Escherichia coli 0 (0) 23 (23.0) 14 (12.4) 12 (15.4)
Klebsiella pneumoniae 0 (0) 11 (11.0) 17 (15.0) 7 (8.9)
Acinetobacter baumannii 0 (0) 4 (4.0) 10 (8.8) 5 (6.4)
Pseudomonas aeruginosa 0 (0) 4 (4.0) 5 (4.4) 5 (6.4)
Proteus mirabilis 0 (0) 7 (7.0) 4 (3.5) 1 (1.3)
Streptococcus pneumoniae 0 (0) 7 (7.0) 0 (0) 3 (3.8)
Staphylococcus aureus 0 (0) 0 (0) 1 (0.9) 3 (3.8)
Other Gram-negatives 0 (0) 1 (1.0) 6 (5.3) 4 (5.1)
Co-morbidities (n, %) 0.109*
Diabetes mellitus type 2 14 (34.2) 23 (23.0) 32 (28.3) 22 (28.2)
Chronic obstructive pulmonary disorder 7 (17.1) 9 (9.0) 25 (22.1) 14 (17.9)
Chronic heart failure 9 (21.9) 16 (16.0) 26 (23.0) 27 (34.6)
Chronic renal disease 5 (12.2) 10 (10.0) 14 (12.4) 9 (11.5)
28-day mortality (n, %) 0 (0) 14 (14.0) 52 (46.0) 46 (58.9) <0.0001*
Hospital mortality (n, %) 0 (0) 14 (14.0) 55 (48.7) 50 (64.1) <0.0001*
Statistically significant differences by ANOVA after post hoc Bonferroni corrections: asepsis vs. SIRS; bseptic shock vs. severe sepsis; csevere sepsis vs. sepsis; dseptic shock
vs. SIRS; esevere sepsis vs. SIRS; fseptic shock vs. sepsis. *refers to the comparison of the distributions of the respective qualitative characteristic between SIRS, sepsis,
severe sepsis and septic shock by the X2 test. APACHE II, acute physiology and chronic health evaluation II; BSI, primary bacteremia; CAP, community-acquired pneumonia;
IQR, interquartile range; IAI, intra-abdominal infection; SD, standard deviation; SIRS, systemic inflammatory response syndrome; WBC, white blood cell; VAP,
ventilator-associated pneumonia; UTI, urinary tract infection.
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a predominant characteristic when a patient with severe
sepsis develops septic shock. Close monitoring from
the start of vasopressors shows that the distribution ofIgM is greater in survivors than in non-survivors from
septic shock.
These conclusions are based on the multilevel approach
of the current study; at first, comparisons between SIRS,
Figure 2 Circulating immunoglobulin M (IgM) at various stages of severity. IgM levels were measured in serum within the first 24 hours from
diagnosis of systemic inflammatory response syndrome (SIRS) (n= 41), of sepsis (n= 100), of severe sepsis (n= 113) and of septic shock (n= 78).
Serum IgM levels for healthy volunteers (n= 35) are also provided. Circles denote outliers. P values of comparisons with patients with septic shock
after Mann-Whitney U test and correction for multiple comparisons are provided.
Figure 3 Changes of circulating immunoglobulin M (IgM) upon worsening of sepsis. IgM was measured: in panel (A) in 13 patients within the
first 24 hours from diagnosis of sepsis and repeated within the first 24 hours of worsening into severe sepsis; in panel (B) in 16 patients within the first
24 hours from diagnosis of sepsis and repeated within the first 24 hours of worsening into septic shock; in panel (C) in 49 patients within the first
24 hours from diagnosis of severe sepsis and repeated within the first 24 hours of worsening into septic shock; and in panel (D) in 5 patients
within the first 24 hours from diagnosis of septic shock and repeated within the first 24 hours of worsening into multiple organ dysfunction. P values
of paired comparisons by the Wilcoxon rank sum test are shown. NS, non-significant.
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Figure 4 Kinetics of immunoglobulin M (IgM) upon progression to shock. Thirty patients with severe sepsis progressed into septic shock.
Serum IgM was measured immediately after start of vasopressors (day 0) until day 6. Results are presented separately for survivors (S) and for
non-survivors (NS). The area under the curve of IgM of survivors (AUCS) and of non-survivors (AUCNS) is provided. In panel (A) S and NS are
distinguished based on their outcome after 28 days; in panel (B) S and NS are distinguished based on their outcome at hospital discharge.
The P values of comparisons between AUCS and AUCNS by Student’s t test are also given. CI, confidence interval.
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shock is the stage of critical illness with the lower circulat-
ing IgM; then measurements at distinct time points that is,
upon initial diagnosis and upon worsening showed that cir-
culating IgM decreases specifically upon progression from
severe sepsis to septic shock; and finally, intense moni-
toring of IgM after the start of vasopressors revealed a
relationship between lacking distribution of IgM and un-
favorable prognosis.
IgM levels in patients with septic shock are reported in
two more studies. In the first study [14], IgM was decreased
in 21 patients with septic shock. Patients were followed up
every 48 hours for five days and they were divided into
those with hypo IgM concentrations and normal IgM con-
centrations. No differences were found between survivors
and non-survivors. In the second study [15], low IgM levels
were reported in the plasma of 62 patients with septic
shock. The IgM concentrations reported by the authors ofthis study were within the range of concentrations reported
in our study. However, the authors failed to define any dif-
ferences in circulating IgM between survivors and non-
survivors [15]. In their study, blood samplings of days 1 and
2, of days 3 and 4 and of days 5 to 7 were reported together
which did not allow measurement of the distribution of cir-
culating IgM as this was done in our study.
IgM is a polyvalent immunoglobulin circulating as a
pentamer [3]. It opsonizes bacteria and primes phagocyt-
osis by neutrophils; it binds and inactivates endotoxins of
Gram-negative bacteria and exotoxins of Gram-positive
cocci; and it also binds and inactivates proinflammatory
host mediators like cytokines. Its role is underscored by
models of experimental sepsis in mice; survival is pro-
longed after induction of sepsis through cecal ligation and
puncture (CLP) within the animals that possess the high-
est potential for IgM-primed phagocytosis [16]. Recent
data coming both from rodents and humans suggest that
Figure 5 Production of immunoglobulin M (IgM) by mononuclear cells. Peripheral blood mononuclear cells (PBMCs) were isolated from 21
healthy volunteers, 24 patients with sepsis, 20 patients with severe sepsis and 11 patients with septic shock. PBMCs were stimulated with
phytohemmaglutin (PHA) that is a selective lymphocyte agonist. Concentrations of IgM, panel (A) and of tumor necrosis factor alpha (TNFα),
panel (B) were measured in supernatants. P values refer to comparisons with the respective production from PBMCs of healthy volunteers by the
Kruskal-Wallis test after correction by Bonferroni. Production of IgM and of TNFα was below the limit of detection in supernatants of unstimulated
PBMCs. Panel (C) shows the percentage of patients with IgM in supernatants above the limit of detection. P values of the indicated comparisons
by the X2 test are provided.
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known as IRA (innate response activator) B cells. These
cells belong to the innate defense system, they contain
large cytoplasmic stores of IgM antibodies and they are
the main effectors of the rapid release of IgM. IRA B cells
are depleted in experimental sepsis and this leads to early
death [17]. The evidence coming from experimental ani-
mal data may help explain the importance of the ex vivo
production of IgM from our patient population. All pa-
tients produced much lower IgM than healthy volun-
teers; this defect was exaggerated in septic shock. Our
findings lead to the hypothesis that during severe sepsis
lymphocytes are hypofunctional for IgM production but
high circulating IgM compensates for the patient’s needs;
once septic shock develops circulating IgM is fully con-
sumed and lymphocytes are completely anergic for any
IgM production.
Two major limitations of the current study should,
however, be acknowledged: (a) the lack of explanation
why septic shock is a specific condition where circulat-
ing IgM is depleted. It is most probable that this is re-
lated with the consumption of circulating IgM during
sepsis worsening and with the inability of B lymphocytesfor IgM production; and (b) the lack of explanation from
our findings why circulating IgM does not differ between
uncomplicated sepsis and septic shock.
Conclusions
The present study managed to identify specific changes
of the kinetics of circulating IgM that are related with
final outcome. These occur when patients with severe
sepsis progress to septic shock. In these patients, the dis-
tribution of IgM is lower among non-survivors. These
findings may guide the design of future RCTs for the
management of septic shock.
Key messages
 Serum levels of IgM are significantly decreased in
septic shock but not in severe sepsis.
 Dramatic changes of serum IgM occur when
patients at severe sepsis progress into septic shock.
In these cases, the distribution of IgM is lower
among non-survivors.
 Circulating lymphocytes of patients render anergic
for the production of IgM.
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